Avidity Biosciences reports Q3 EPS (82c), consensus (93c)

Reports Q3 revenue $2.48M, consensus $2.37M. Cash, cash equivalents and marketable securities remained constant at $405.5M as of September 30, 2022, and December 31, 2021, respectively. "Consistent with our guidance for 2022, we have progressed three programs addressing three distinct rare diseases into clinical development, and we remain on track for our preliminary assessment of the MARINA trial this quarter," said Sarah Boyce, president and CEO. "Our team continues to execute on our plan as we advance AOC 1020 for FSHD in the FORTITUDE trial and AOC 1044 for DMD in the EXPLORE44 trial. With close to 40 participants enrolled in the MARINA trial, we continue to gather data on AOC 1001 as we work to resolve the recent partial clinical hold on new participant enrollment as swiftly as possible."